Adidas Leggings Damen Günstig

, when initially launched, proved to be a very promising drug for treating patients suffering from Type II diabetes who are not insulin dependent.  Yet, since its approval in 1999, numerous severe and life-threatening side effects have been attributed to Actos: bladder cancer, heart disease and heart failure, bone fractures, and , the release of muscle fibers into the blood stream which often leads to liver damage.

The many disturbing reports of unfavorable side effects presented to Takeda Pharmaceuticals, the manufacturer of Actos, and the FDA’s monitoring agency, the Adverse Events Reporting System (AERS), required the FDA to publish its first set of warnings to the public in 2007.  This first statement concluded “that the drug may cause or worsen heart failure in certain patients.”  Additionally, the FDA required Actos to carry a new label including a black-box warning, the FDA most severe warning, and an updated warning in the medication’s Warnings and Precautions guide.  Over the next five years, numerous other notifications were published by the FDA in regards to Actos’ link to bladder cancer, bone fracture, and rhabdomyolysis.   In July 2010, Actos was even recalled from France and Germany because of its link to an increased risk of developing bladder cancer after long-term use (more than one year).

The manufacturer of Actos, Takeda Pharmaceuticals, a subsidiary of the Japan’s largest drug company Takeda Pharmaceutical Company Limited, in conjunction with the U. S. based Eli Lilly